157 related articles for article (PubMed ID: 12618329)
1. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase.
Shen LJ; Lin WC; Beloussow K; Shen WC
Cancer Lett; 2003 Mar; 191(2):165-70. PubMed ID: 12618329
[TBL] [Abstract][Full Text] [Related]
2. RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells.
Wu FL; Liang YF; Chang YC; Yo HH; Wei MF; Shen LJ
J Biomed Sci; 2011 Apr; 18(1):25. PubMed ID: 21453546
[TBL] [Abstract][Full Text] [Related]
3. Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells.
Wu FL; Yeh TH; Chen YL; Chiu YC; Cheng JC; Wei MF; Shen LJ
Mol Pharm; 2014 Aug; 11(8):2777-86. PubMed ID: 24950134
[TBL] [Abstract][Full Text] [Related]
4. Recombinant arginine deiminase reduces inducible nitric oxide synthase iNOS-mediated neurotoxicity in a coculture of neurons and microglia.
Yu HH; Wu FL; Lin SE; Shen LJ
J Neurosci Res; 2008 Oct; 86(13):2963-72. PubMed ID: 18627024
[TBL] [Abstract][Full Text] [Related]
5. Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L; Savaraj N
Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
[TBL] [Abstract][Full Text] [Related]
6. Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis.
Noh EJ; Kang SW; Shin YJ; Kim DC; Park IS; Kim MY; Chun BG; Min BH
Mol Cells; 2002 Feb; 13(1):137-43. PubMed ID: 11911465
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Kim JH; Kim JH; Yu YS; Kim DH; Min BH; Kim KW
Oncol Rep; 2007 Dec; 18(6):1373-7. PubMed ID: 17982619
[TBL] [Abstract][Full Text] [Related]
8. Recombinant arginine deiminase as a potential anti-angiogenic agent.
Beloussow K; Wang L; Wu J; Ann D; Shen WC
Cancer Lett; 2002 Sep; 183(2):155-62. PubMed ID: 12065090
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Sugimura K; Ohno T; Kusuyama T; Azuma I
Melanoma Res; 1992 Sep; 2(3):191-6. PubMed ID: 1450673
[TBL] [Abstract][Full Text] [Related]
11. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Shen LJ; Beloussow K; Shen WC
Cancer Lett; 2006 Jan; 231(1):30-5. PubMed ID: 16356828
[TBL] [Abstract][Full Text] [Related]
12. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
Tsai WB; Aiba I; Lee SY; Feun L; Savaraj N; Kuo MT
Mol Cancer Ther; 2009 Dec; 8(12):3223-33. PubMed ID: 19934275
[TBL] [Abstract][Full Text] [Related]
13. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
14. Canavanine-resistant variants of human lymphoblasts.
Jacoby LB
Somatic Cell Genet; 1978 Mar; 4(2):221-31. PubMed ID: 663801
[TBL] [Abstract][Full Text] [Related]
15. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
16. Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells.
Wheatley DN; Campbell E
Br J Cancer; 2003 Aug; 89(3):573-6. PubMed ID: 12888832
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
[TBL] [Abstract][Full Text] [Related]
18. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
19. Depletion of arginine by recombinant arginine deiminase induces nNOS-activated neurotoxicity in neuroblastoma cells.
Lin SE; Wu FL; Wei MF; Shen LJ
Biomed Res Int; 2014; 2014():589424. PubMed ID: 25126568
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.
Agrawal V; Woo JH; Mauldin JP; Jo C; Stone EM; Georgiou G; Frankel AE
Anticancer Drugs; 2012 Jan; 23(1):51-64. PubMed ID: 21955999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
